Last reviewed · How we verify

NCT02922647: GRECCAR10

Suprapubic Versus Transurethral Catheterization After Rectal Resection With Low Anastomosis for Cancer in Males

Completed NA Last updated 21 July 2022
What this trial tests

NA trial testing suprapubic catheterization in Infection in 240 participants. Completed in 16 April 2021.

Timeline
14 October 2016
Primary endpoint
18 May 2020
16 April 2021

Quick facts

Lead sponsorUniversity Hospital, Grenoble
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment240
Start date14 October 2016
Primary completion18 May 2020
Estimated completion16 April 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

18 and older, male only, with Infection or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to compare the urinary tract infection rate on the four postoperative day between the 2 groups of patients who have undergone total mesorectal excision for cancer and low anastomosis, with either suprapubic or transurethral catheterization.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Suprapubic versus transurethral catheterization for bladder drainage in male rectal cancer surgery (GRECCAR10), a randomized clinical trial.
    Trilling B, Tidadini F, Lakkis Z, Jafari M, et al · · 2024 · cited 2× · PMID 38954131 · DOI 10.1007/s10151-024-02950-2

Verify or expand the search:

Other recruiting trials for Infection

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02922647.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing